Piperidine renin inhibitors

US8580823B2 · kind B2 · utility

Assignee

• Vitae Pharmaceuticals, LLC · US

Inventors

• John J. Baldwin · Gwynedd Valley, US
• David A. Claremon · Audubon, US
• Colin M. Tice · Ambler, US
• Salvacion Cacatian · Conshohocken, US
• Lawrence Wayne Dillard · Yardley, US
• Alexey V. Ishchenko · Somerville, US
• Jing Yuan · Lansdale, US
• Zhenrong Xu · Forest Park, US
• Gerard McGeehan · Chester Springs, US
• Wei Zhao · North Potomac, US
• Robert D. Simpson · Wilmington, US
• Suresh B. Singh · Kendall Park, US
• Lanqi Jia · Horsham, US
• Patrick T. Flaherty · Pittsburgh, US

Key dates

• Filing date: May 11, 2012
• Grant date: Nov 12, 2013
• Expiry date: May 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to aspartic protease inhibitors represented by the following structural formula:or a pharmaceutically acceptable salt thereof.The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I).Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.